HIV / AIDS in the News

New WHO guidance on HIV disclosure for children and adolescents - World Health Organization (WHO)

 

Integrating HIV, viral hepatitis and sexually transmitted infections with primary health care: learning from countries - World Health Organization (WHO)

 

WHO prequalifies the first triple diagnostic test for HIV, hepatitis B and syphilis, a milestone toward global disease elimination goals - World Health Organization (WHO)

 

Gilead Sciences (GILD) Reaches Deal to Offer HIV Vaccine to Low and Middle-Income Nations - Insider Monkey

 

Gilead, GSK/ViiV, Merck Present New HIV PrEP Frontiers at IAS25 - BioSpace

 

Merck’s MK-8527 Advances to Phase 3 for Once-Monthly HIV Prevention - Contagion Live

 

Toxic Epidermal Necrolysis in an HIV-Infected Patient - Cureus

 

Toxic Epidermal Necrolysis in an HIV-Infected Patient - Cureus

 

UNAIDS welcomes new WHO guidelines on Lenacapavir - UNAIDS

 

Op-ed: HIV surge should ring alarm bells for G7 leadership - The Parliament Magazine

 

A serological household survey on social determinants of the generalized HIV epidemic in southern Brazil - Nature

 

ViiV expands licence to allow generic HIV treatment production for low-income countries - Reuters

 

Gilead's twice-yearly HIV PrEP set for wider rollout - pharmaphorum

 

HIV Treatment Access: Aurobindo to Manufacture Long-Acting HIV Injection for 133 Countries - Deccan Herald

 

WHO approves injectable HIV drug lenacapavir for high-risk communities - Business Standard

 

ViiV Healthcare expands MPP licensing deal for long-acting HIV treatment - World Pharmaceutical Frontiers

 

Are UC researchers any closer to finding a functional cure for HIV? - WVXU

 

ViiV Healthcare data show 89% of treatment-naïve people with HIV choose to switch to long-acting injectable Vocabria + Rekambys from daily pills after achieving rapid viral suppression - BioSpace

 

Yeztugo's Double-Edged Sword: Gilead's HIV Breakthrough and the Global Stakes - AInvest

 

WHO recommends a twice-a-year injection for HIV prevention - Times of India

 

Using HIV Drugs to Fight Alzheimer’s - Being Patient

 

Merck Launches Phase 3 Trials for Once-Monthly Oral HIV Prevention Drug MK-8527 - geneonline.com

 

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025 - BioSpace

 

Sanford specialist explains new HIV treatment - KFYR-TV

 

WHO Adds Lenacapavir to Its HIV PrEP Recommendations Amid Underutilization of PrEP and Severe PEPFAR Funding Cutbacks | IAS 2025 - Managed Healthcare Executive

 

Sanford specialist explains new HIV treatment - KFYR-TV

 

New mRNA Tech Exposes HIV Virus Hiding Dormant in Cells, Early Experiments Find - Nurse.org

 

Updated licensing agreement marks “major milestone” in global HIV response - European Pharmaceutical Review

 

South African Health Official Supports New HIV Guidelines, Shares Importance of Integrated Care | IAS 2025 - Managed Healthcare Executive

 

WHO recommends Gilead's twice-yearly injection for HIV prevention - Reuters